According to Syqe Medical, the company has received regulatory approval from the Israeli Ministry of Health to launch its metered-dose cannabis inhaler in Israel for the treatment of pain. The inhaler, which was previously available only for hospital use, will now be available to licensed patients. In 2016, the company announced that Teva would distribute the … [Read more...] about Syqe launches cannabis inhaler in Israel
Regulatory
Bevespi Aerosphere gets Japanese approval
The Japanese Ministry of Health, Labour and Welfare has approved AstraZeneca's Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of COPD, the company said. Bevespi Aerosphere has been approved for the treatment of COPD in the US since 2016 and in the EU since December 2018. Canada and Australia have also approved the inhaler, which is … [Read more...] about Bevespi Aerosphere gets Japanese approval
Afrezza inhaled insulin approved in Brazil
The Brazilian Health Regulatory Agency (ANVISA) has approved Afrezza inhaled insulin for the treatment of diabetes, and the DPI is expected to be launched in Brazil by the end of 2019, MannKind Corporation said. MannKind announced in May 2017 that it had signed a Brazilian distribution deal for Afrezza with Biomm. Afrezza was approved by the FDA in 2014 and is … [Read more...] about Afrezza inhaled insulin approved in Brazil
According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
Vectura Group and Sosei Group each said that they are owed $2.5 million milestone payments from Novartis after the EU accepted Novartis's MAA for its QVM149 indacaterol/glycopyrronium/mometasone furoate DPI for the treatment of asthma that is inadequately controlled. Vectura said that approval of the MAA would trigger an additional milestone payment of $5 million. … [Read more...] about According to Vectura and Sosei, Novartis has filed MAA for triple therapy DPI
Akorn’s azelastine hydrochloride nasal spray approved by the FDA
The FDA has approved an ANDA for Akorn's generic azelastine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis in patients 5 years old and older and for vasomotor rhinitis in patients 12 and older, the company said. According to the FDA web site, ANDA #207610 was submitted by Hi-Tech Pharmacal, which was acquired by Akorn in 2014. There … [Read more...] about Akorn’s azelastine hydrochloride nasal spray approved by the FDA
Nayzilam midazolam nasal spray approved by the FDA
UCB said that the FDA has approved an NDA for Nayzilam midazolam nasal spray (formerly USL261) for the treatment of seizure clusters in epilepsy patients aged and older. UCB acquired the nasal spray from former Upsher Smith subsidiary Proximagen in April 2018 and announced in August 2018 that the FDA had accepted the NDA. The midazolam nasal spray was granted … [Read more...] about Nayzilam midazolam nasal spray approved by the FDA
PADAC votes to recommend approval of Bronchitol
The FDA's Pulmonary‐Allergy Drugs Advisory Committee (PADAC) has voted to recommend approval of Chiesi's NDA for Bronchitol DPI for the treatment of cystic fibrosis in adult patients. According to Bronchitol developer Pharmaxis, Chiesi re-submitted the NDA in December 2018. Bronchitol is already approved in Australia, Russia, and in Europe, where it was okayed in … [Read more...] about PADAC votes to recommend approval of Bronchitol
Glenmark gets Russian approval for Momate Rhino nasal spray
According to Glenmark Pharmaceuticals, the Russian Ministry of Healthcare has approved the company's Momate Rhino mometasone furoate nasal spray for over-the-counter sales for the treatment of allergic rhinitis in adults. Glenmark Pharmaceuticals Senior VP and Head,"Asia, Russia & CIS region, Csaba Kantor commented, "Glenmark has built strong capabilities in … [Read more...] about Glenmark gets Russian approval for Momate Rhino nasal spray
FDA approves first generic of Narcan nasal spray
The FDA has announced the final approval of Teva's ANDA for a generic naloxone hydrochloride nasal spray. According to the announcement, the agency tentatively approved the ANDA in June 2018. Opiant Pharmaceutical's Narcan nasal spray was approved in a 4 mg dose version by the FDA in November 2015, and a 2 mg dose version of Narcan was approved in January 2017. … [Read more...] about FDA approves first generic of Narcan nasal spray
FDA approves Akorn’s ANDA for fluticasone propionate nasal spray
Akorn announced that the FDA has approved an ANDA for fluticasone propionate nasal spray submitted by Hi Tech Pharmacal, which was acquired by Akorn in 2014. The nasal spray is a generic of GSK's Flonase, which was approved for OTC sales in the US in 2014. Akorn President and CEO Douglas Boothe said, “We are excited to add to our fluticasone franchise and look … [Read more...] about FDA approves Akorn’s ANDA for fluticasone propionate nasal spray